Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention by Robinson, D. G. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2018
Psychopharmacological Treatment in the RAISE-
ETP Study: Outcomes of a Manual and Computer
Decision Support System Based Intervention
D. G. Robinson
Zucker School of Medicine at Hofstra/Northwell
N. R. Schooler
C. U. Correll
Zucker School of Medicine at Hofstra/Northwell
M. John
Northwell Health
B. T. Kurian
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Psychiatry Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Robinson DG, Schooler NR, Correll CU, John M, Kurian BT, Marcy P, Miller AL, Pipes R, Trivedi MH, Kane JM.
Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based
Intervention. . 2018 Jan 01; 175(2):Article 3934 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/3934.
Free full text article.
Authors
D. G. Robinson, N. R. Schooler, C. U. Correll, M. John, B. T. Kurian, P. Marcy, A. L. Miller, R. Pipes, M. H.
Trivedi, and J. M. Kane
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/3934
Psychopharmacological Treatment in the RAISE-ETP Study: 
Outcomes of a Manual and Computer Decision Support System 
Based Intervention
Delbert G Robinson, M.D.1,2,3, Nina R. Schooler, Ph.D.3,4, Christoph U. Correll, M.D.1,2,3,5, 
Majnu John, Ph.D.1,3,6, Benji T. Kurian, M.D., M.P.H.7, Patricia Marcy, B.S.N.3, Alexander L. 
Miller, M.D.8, Ronny Pipes, M.A., LPC-S7, Madhukar H. Trivedi, M.D.7, and John M. Kane, 
M.D.1,2,3,5
1The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, 
NY, USA
2Hofstra Northwell School of Medicine, Departments of Psychiatry and of Molecular Medicine, 
Hempstead, NY, USA
3The Zucker Hillside Hospital, Psychiatry Research, North Shore-Long Island Jewish Health 
System, Glen Oaks, NY, USA
4SUNY Downstate Medical Center, Department of Psychiatry, Brooklyn, NY, USA
5Albert Einstein College of Medicine, Department of Psychiatry and Behavioral Sciences, Bronx, 
NY, USA
Location of work and address for reprints: Corresponding author: Delbert Robinson, M.D., The Zucker Hillside Hospital, 75-59 263 
Street, Glen Oaks, N.Y. 11004, drobinso@northwell.edu. 
Previous Presentation:
Partial data were presented at the 9th International Congress on Early Psychosis, Tokyo, Japan, November 17–19, 2014 and the 
International Congress on Schizophrenia Research, Colorado Springs, Colorado, March 28–April 1, 2015.
Disclosures:
Dr. Robinson has been a consultant to Asubio, Costello Medical Consulting, Innovative Science Solutions, Janssen, Neurocrine, 
Otsuka and Shire and he has received research support from Otsuka. Dr. Schooler has served on Advisory Boards or as a consultant for 
Alkermes, Allergan, Eli Lilly, Forum (formerly EnVivo), Roche and Sunovion. She has received grant/research support from Otsuka. 
Dr. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Actavis, Actelion, Alexza; Alkermes, 
Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, 
Medavante, Medscape, Merck, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, Takeda, Teva, and Vanda. He has 
received grant support from Bristol-Myers Squibb, Janssen/J&J, Novo Nordisk A/S, Otsuka and Takeda. Ms. Marcy is a shareholder in 
Pfizer and is the executive director of the Vanguard Research Group which has received research support from Otsuka and Janssen. Dr. 
Kurian has received grant support from Johnson & Johnson and Naurex (now owned by Allergan). Dr. Miller has received payments 
for service on Data Monitoring Committees for two studies sponsored by Otsuka. Dr Trivedi has been a consultant for Alkermes Inc., 
Allergan, Arcadia Pharmaceuticals Inc., AstraZeneca, Brintellix, BMS, Cerecor, Eli Lilly & Company, Forest, Health Research 
Associates, Johnson & Johnson, Lundbeck, Medscape, MSI Methylation Sciences Inc., Merck, Naurex Inc., Nestle Health Science – 
Pamlab Inc., One Carbon Therapeutics, Otsuka America Pharmaceuticals Inc., PamLab, Pfizer Inc., Roche, SHIRE Developmentand 
Takeda Pharmaceuticals and has received grant support from Johnson and Johnson. Dr. Kane has been a consultant for Alkermes, 
Amgen, Bristol-Myers Squibb, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck. Intracellular Therapies, 
Janssen Pharmaceutica, Johnson and Johnson, Merck, Novartis, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion and Teva. Dr. Kane 
has received honoraria for lectures from Bristol-Myers Squibb, Janssen, Genentech, Lundbeck and Otsuka. Dr. Kane is a Shareholder 
in MedAvante, Inc. and the Vanguard Research Group. Dr. John and Mr. Pipes have no financial interests to disclose.
The authors and their associates provide training and consultation about implementing NAVIGATE treatment that can include 
compensation. These activities started only after data collection for the article was completed. At the time of publication, Dr. Robinson 
had received compensation for these activities.
Rights to the COMPASS system are held by the Feinstein Institute for Medical Research, the University of Texas Southwestern and 
the Research Foundation for Mental Health.
HHS Public Access
Author manuscript
Am J Psychiatry. Author manuscript; available in PMC 2018 August 01.
Published in final edited form as:
Am J Psychiatry. 2018 February 01; 175(2): 169–179. doi:10.1176/appi.ajp.2017.16080919.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6Hofstra University, Department of Mathematics, Hempstead, NY, USA
7University of Texas Southwestern Medical Center, Dallas, TX, USA
8University of Texas Health Science Center at San Antonio, Department of Psychiatry, San 
Antonio, TX, USA
Abstract
Objective—RAISE-ETP compared NAVIGATE, a comprehensive program for first-episode 
psychosis, to clinician-choice treatment over two years. Quality of life and psychosis and 
depressive symptom outcomes were better with NAVIGATE. Compared with prior comprehensive 
first-episode psychosis interventions, NAVIGATE medication prescription included unique 
elements of 1) detailed first-episode psychotropic medication guidelines and 2) a computerized 
decision support system to facilitate shared decision making regarding prescriptions. We present 
comparisons between the treatment conditions of the psychotropic medications prescribed, side 
effect experienced, metabolic outcomes and scores from the Adherence Estimator that assesses 
beliefs related to intentional non-adherence.
Methods—Prescription data were obtained monthly using the Service Use and Resource Form. 
At baseline, 3, 6, 12, 18 and 24 months, participants reported whether they were experiencing any 
of 21 common antipsychotic side effects, vital signs were obtained, fasting blood samples 
collected and the Adherence Estimator completed.
Results—Over the 2 years, the 223 NAVIGATE participants compared to the 181 clinician-
choice participants had more medication visits, were more likely to be prescribed an antipsychotic 
and also an antipsychotic conforming to NAVIGATE prescribing principles and were less likely to 
be prescribed an antidepressant. NAVIGATE participants experienced fewer side effects and also 
gained less weight; other vital signs and cardiometabolic laboratory findings did not differ 
between treatments. Adherence Estimator scores decreased (fewer beliefs associated with non-
adherence) with NAVIGATE but not clinician-choice care.
Conclusions—As part of comprehensive care services, medication prescription can be 
optimized for first-episode psychosis, contributing to better outcomes with less side effect burden 
than standard care.
Clinical Trials registration—NCT01321177: An Integrated Program for the Treatment of First 
Episode of Psychosis (RAISE-ETP), http://www.clinicaltrials.gov/ct2/show/NCT01321177
Introduction
Comprehensive specialty care treatment for early psychosis has been strongly advocated 
(e.g. (1)) and several randomized comparisons performed (2–8). Given the critical role of 
medication treatment, it is notable that comprehensive specialty care interventions varied 
widely in how much medication treatment was specified and that such limited information 
was provided on treatment goals and guidelines, prescriber training and treatment delivery. 
In published manuscripts, medication prescription was not mentioned for the GET UP 
PIANO TRIAL intervention (7); the STEP intervention (8) included “psychotropic 
prescription”; Grawe and colleagues (3) used antipsychotics “at the lowest effective dose”; 
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the LEO study (2) intervention employed “low dose atypical antipsychotic regimens” while 
COAST (6) used “optimum atypical medication”, and OPUS (4) used medication treatment 
“designed individually according to national guidelines”. In contrast, medication 
prescription in the NAVIGATE intervention of the Recovery After an Initial Schizophrenia 
Episode - Early Treatment Program (RAISE-ETP) included unique elements of 1) program-
developed first-episode medication guidelines, 2) a computerized decision support system to 
support shared decision making regarding prescriptions and 3) training and ongoing support 
for prescribers throughout the study.
We examined NAVIGATE’s effects on prescription practices and measures of general side 
effects, vital signs and cardiometabolic outcomes using data from the RAISE-ETP study 
(5,9) comparing NAVIGATE treatment with clinician-choice Community Care. These 
analyses complement findings (5) of better symptom Positive and Negative Syndrome Scale 
(10) and Calgary Depression Scale for Schizophrenia (11) outcomes with NAVIGATE 
compared with Community Care.
Methods
NAVIGATE treatment (12) included coordinated medication management, psychoeducation, 
resilience-focused individual therapy and supported employment and education. NAVIGATE 
team members supported each other’s efforts including adherence to NAVIGATE medication 
guidelines. Individual resilience-focused therapy included modules about medications and 
health-promoting behaviors.
Medication procedures
Research data and treatment guidelines (13–17) support distinctive medication strategies for 
first-episode and multi-episode patients. Our approach to assisting busy clinicians at our 
non-academic “real world” sites to incorporate specialized first-episode treatment strategies 
into their work started by developing first-episode medication guidelines based upon review 
of the treatment literature. Medication recommendations were limited to marketed agents 
given the community facilities setting. NAVIGATE treatment used a shared decision making 
model (18). For medication selection, patients and prescribers chose among medications 
with equivalent evidence based upon patient factors and preferences. The shared decision 
making framework plus the failure of any antipsychotic to demonstrate superior efficacy for 
initial treatment of psychosis led to the decision to group recommended medications into 
treatment stages instead of a single medication algorithm. Medication grouping criteria 
included data from first-episode or adolescent patients with psychotic disorders and low side 
effect risk. Symptom remission rather than symptom improvement was the treatment goal. If 
satisfactory initial response was not obtained, medications were chosen from subsequent 
stage groups. The antipsychotics available in the United States during guideline development 
with data from contemporary studies with first-episode or adolescent populations were 
aripiprazole, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone and 
ziprasidone. Because of concerns about side effects for chlorpromazine, clozapine, 
haloperidol and olanzapine and for less maintenance treatment efficacy for haloperidol 
(19,20), these medications were excluded from the stage 1 group (consisting of the 
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remaining studied agents aripiprazole, quetiapine, risperidone and ziprasidone). Stage 2 
agents were the stage 1 agents plus chlorpromazine, haloperidol and olanzapine; clozapine 
was a stage 3 agent. For each medication, first-episode dosing guidelines were developed 
(e.g. for risperidone, starting dose of 1–2 mg/day, target dose of 3–4 mg/day and maximum 
dose of 8 mg/day). Over the two-year RAISE-ETP treatment duration, continuous 
antipsychotic treatment was recommended. Patients and prescribers evaluated the potential 
benefits and disadvantages of switching antipsychotics for participants who entered RAISE-
ETP with prescriptions not conforming to NAVIGATE stage 1 principles. Participants who 
agreed to take antipsychotics but not a NAVIGATE-preferred medication were prescribed 
their preferred agent; participants who declined to take any antipsychotic had ongoing 
prescriber monitoring visits. Side effect management strategies (dose reduction being the 
usual initial strategy) and for monitoring and treatment of cardiometabolic abnormalities 
were also provided. Since the depressive symptoms of first-episode patients often remit with 
antipsychotic treatment alone (21), prescription of adjunctive antidepressants for all first-
episode patients with depressive symptoms was not advised. Instead, consideration of the 
persistence and severity of depression was suggested when making decisions about 
adjunctive antidepressants. The detailed NAVIGATE medication manual is available at (22).
Participants and prescribers used COMPASS, a NAVIGATE-developed computer clinical 
decision making tool accessed via a secure web-based platform. COMPASS was designed to 
facilitate patient-prescriber communication. Participants entered information about 
symptoms, side effects, treatment preferences, medication adherence and attitudes, and 
substance use into COMPASS before meeting with prescribers. Vital signs data and 
laboratory test results were also entered. Using a measurement-based approach, the 
prescriber’s assessments, also entered directly into COMPASS, were modified/informed 
based upon these prior entered data. Integrating participant treatment priorities and the 
prescriber’s assessments, COMPASS provided suggested guideline treatments. Prescribers 
and participants then made medication decisions informed by these recommendations. 
NAVIGATE guidelines recommended a prescriber visit at least monthly for the first two 
years of treatment.
NAVIGATE prescriber training included an in-person group two-day session on NAVIGATE 
principles followed by individual training via teleconferencing on technical aspects of 
COMPASS. Monthly group prescriber teleconferences with the NAVIGATE Central Team 
included group feedback about clinical challenges and NAVIGATE treatment options for 
these and review of relevant psychosis literature.
RAISE-ETP study
This report focuses on the first two years of patient participation, the minimum by design for 
all participants. Patients aged 15 to 40 years receiving treatment for a first-episode of 
psychosis due to schizophrenia, schizoaffective disorder, schizophreniform disorder, brief 
psychotic disorder, or psychotic disorder not otherwise specified and who had taken ≤6 
months of antipsychotics during their lifetime were recruited from 34 community mental 
health treatment facilities nationwide without preexisting first-episode specialty care 
programs. Written informed consent was obtained from adult participants; written consent 
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from guardians and written assent from participants younger than 18. RAISE-ETP was 
conducted under the guidance of the NIMH Data and Safety Monitoring Board and of 
Institutional Review Boards at the coordinating center and the sites.
RAISE-ETP employed cluster randomization. The 17 randomly-assigned NAVIGATE sites 
recruited 223 participants and the 17 Community Care sites 181 participants. Community 
Care clinicians were trained on recruitment, informed consent and study assessment 
procedures but received no guidance about treatment approaches. The study design and 
assessments have been previously described (9). Monthly, patient self-report data on 
prescription (medication and dose) and on number of medication management visits were 
obtained with the Service Use and Resource Form (23). At baseline, 3, 6, 12, 18 and 24 
months, participants reported in a yes/no format whether they had experienced during the 
past 30 days 21 common side effects of antipsychotic medications (dizziness, blurred vision, 
excess saliva, nausea, constipation, increased appetite, weight gain, weight loss, restlessness, 
shaking, rigidity, fatigue, drowsiness, excess sleep, insomnia, decreased libido, other sexual 
problems, breast swelling or discharge, impaired sexual performance and amenorrhea). 
Concurrently, vital signs were obtained and fasting blood samples collected. Participants 
taking medications also completed the Adherence Estimator, a self-report scale (24) 
measuring beliefs related to intentional non-adherence that has been validated against 
pharmacy claims (25).
Statistical analyses
As RAISE-ETP participants had psychotic disorders, our paramount medication question 
was whether NAVIGATE compared with Community Care treatment was associated with 
greater likelihood of antipsychotic prescription. We also compared the likelihood of 
participants receiving a prescription that conformed to NAVIGATE stage 1 (“first-line”). By 
study month, we determined if participants were prescribed antipsychotic mono-therapy 
with a NAVIGATE stage 1 antipsychotic. We allowed a broad range of antipsychotic doses 
(instead of our targeted dose ranges) to qualify as first-line to allow for low doses for 
antipsychotic initiation and higher doses for management of treatment-resistance (e.g. the 
qualifying dose range for risperidone was 1–8 mg per day, based upon 1mg/day being the 
NAVIGATE recommended lowest starting dose and 8 mg/day the highest dose). Participants 
receiving concurrent stimulants were classified as not being prescribed first-line 
medications; participants prescribed antipsychotic mono-therapy with paliperidone at 
approved doses were classified as being prescribed a first-line medication (NAVIGATE 
training included review of the administration advantages of paliperidone palmitate over 
risperidone microspheres). Given that depression outcomes were better with NAVIGATE 
than Community Care, we also compared the likelihood of antidepressant prescription 
between conditions. Other medication explorations: Antipsychotic prescription involves 
choice of agent and dose. To characterize these, we examined the likelihood of the most 
commonly prescribed agents being prescribed (irrespective of dose or other medications 
prescribed) and the mean modal dose for oral formulations of each agent.
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General side effects
The primary measure was the total number of side effects (excluding amenorrhea being not 
applicable to male participants). Secondary measures were amenorrhea and a priori side 
effect groupings (sedation, extrapyramidal symptoms, anticholinergic side effects, increased 
appetite or weight gain and sexual problems). A side effect group was considered present if 
any side effect within that group was present.
Longitudinal analyses of the any-antipsychotic-use (yes/no) outcome and other binary 
outcomes reported in Table 1 and Supplemental Table 2 were performed using a generalized 
linear mixed models analysis with a logit link. PROC GLIMMIX in SAS 9.4 was used. Each 
subject’s modal dose was calculated and the mean modal dose was compared between 
conditions using a mixed models analysis with a random intercept for site. Longitudinal 
analysis of the cardiometabolic outcomes (Table 3) and total number of side effects (Table 4) 
was performed with mixed models using the PROC MIXED procedure in SAS 9.4. The 
mixed models approach takes into account the within subject correlation of the repeated 
measurements. The difference in the trajectories between the two treatment groups was 
assessed by including a time-by-treatment interaction term in the mixed models. Least 
square means which estimate the population marginal means for a balanced design are 
reported in Table 3 and 4. In all longitudinal analysis, cluster correlation within site was 
addressed by including a random intercept for subjects nested within sites. The limited 
number of clusters in clustered randomized trials can cause an imbalance between treatment 
groups on baseline measures, potentially confounding the relationship between treatments 
and outcomes. As per the overall RAISE-ETP statistical analysis plan (5,26), variables with 
significant baseline group imbalance were included as covariates in our analyses if they were 
correlated with the outcome of interest at a level of ≥.30.
Multiple comparisons adjustments were done by controlling the False Discovery Rate (FDR) 
using the Benjamini-Hochberg’s procedure (27,28). The R ‘multtest’ package was used. 
FDR correction was applied to groups of analyses that addressed the same clinical question. 
The blocks were: medication classes (Table 1); specific agents (Table 1); daily dose (Table 
2); vital signs (Table 3); laboratory findings (Table 3); number of side effects (Table 4) and 
specific side effects (Supplemental Table 2). Significance was declared for analyses with 
FDR-corrected p-values <0.05.
Odds ratios in Table 1 were converted to Cohen’s d using the formula . 
Elsewhere, effect sizes of the difference between least square means were calculated using 
the formula: , where t = t-value and df = degrees of freedom.
Results
Participants
Supplemental Table 1 presents participant characteristics. Briefly, 73% were men, the most 
frequent racial backgrounds were Caucasian (54%) and African-American (37%), the mean 
age was 23 years and the most frequent diagnoses were schizophrenia (53%) and 
schizophreniform disorder (14%).
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COMPASS implementation
Two hundred eleven of the 223 NAVIGATE participants (94.6%) completed one or more 
COMPASS visits. During their first 2 years of study participation, NAVIGATE participants 
completed 3004 COMPASS assessments.
Number of medication visits
As presented in Figure 1, NAVIGATE compared with Community Care participants had 
significantly more medication visits (treatment-by-time interaction F=3.78, df=23, 9246, 
p<0.0001; effect of treatment, F=12.80, df=1, 9246, p=0.0003). Over the 2 years, the least 
square means estimate of the number of medication visits per month was 0.292 (95% CI: 
0.226, 0.357) for Community Care and 0.554 (95% CI: 0.423, 0.685) for NAVIGATE.
Medication prescription
As shown in Table 1, NAVIGATE compared with Community Care participants were 
significantly more likely to receive an antipsychotic prescription (odds ratio 3.734, 95% CI: 
1.709, 8.162) and less likely (odds ratio 0.391, 95% CI: 0.162, 0.943) to receive an 
antidepressant prescription.
Over the trial, NAVIGATE participants were more likely to receive prescriptions conforming 
to NAVIGATE first-line principles (odds ratio 2.189, 95% CI:1.084, 4.421). Prescriptions at 
study entry for NAVIGATE and Community Care participants were equally likely to not 
conform with NAVIGATE first-line principles (t=−0.49, df=744, p=0.6263). In post hoc 
analyses of participants who were not receiving a NAVIGATE first-line prescription at 
baseline, 62.7% of the 110 NAVIGATE participants compared with 44.4% of the 90 
Community Care participants later received a NAVIGATE first-line prescription (odds ratio 
= 2.065, 95% CI = 1.024, 4.164, t=2.11, df=31, p=0.0432).
As shown in Tables 1 and 2, the specific antipsychotics prescribed and mean modal dose did 
not significantly differ between conditions for any of the major antipsychotics. At a trend 
level, NAVIGATE compared with Community Care participants were more likely to be 
prescribed aripiprazole and less likely to be prescribed haloperidol.
Vital Sign and Cardiometabolic Outcomes
As presented in Table 3, both weight and BMI analyses revealed significant treatment-by-
time interactions. The estimated mean increase in BMI from baseline to month 24 was 2.10 
(95% CI:1.32, 2.89) for NAVIGATE and 2.44 (95% CI:1.90, 2.99) for Community Care 
participants; the corresponding estimated weight gain was 6.51 (95% CI:4.61, 8.41) kg for 
NAVIGATE and 7.31 (95% CI:5.62, 9.00) for Community Care participants. No significant 
treatment-by-time interactions or treatment effects were detected in analyses of other vital 
signs data or of lipid or carbohydrate metabolism measures.
General Side Effects
Analysis of the number of side effects revealed a significant treatment-by-time interaction. 
As shown in Table 4, NAVIGATE and Community Care participants reported equal number 
of side effects at baseline but NAVIGATE participants reported fewer side effects at 
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subsequent visits (significantly less at month 6 and 12 and at a trend level at months 3, 18 
and 24). A secondary analysis controlling for antipsychotic prescription similarly revealed 
an advantage for NAVIGATE treatment (treatment- by-time interaction, F=2.88, df=5,1087, 
p=0.004). Supplemental Table 2 presents the analyses of side effect groups. NAVIGATE 
participants were significantly less likely to have sedation or anticholinergic side effects and 
at a trend level less extrapyramidal symptoms, appetite increase and sexual dysfunction.
Adherence Estimator
Scores did not differ at baseline and decreased (fewer beliefs associated with non-adherence) 
significantly among NAVIGATE but not Community Care participants (treatment-by-time 
interaction F=2.46, df=5,940, p=0.0316). Least square means estimates of baseline and 24 
month scores were 8.3278 (SE=0.8577) and 6.0870 (SE=0.6855) with NAVIGATE (change 
decrease of 2.2408 (SE=1.0622)) and 7.1239 (SE=0.8015) and 7.8996 (SE=0.8052) with 
Community Care (change increase of 0.7757 (SE=0.9308)).
Discussion
The NAVIGATE model was developed to treat a specialized population, patients with first-
episode schizophrenia and related disorders, in non-academic “real world” settings. An 
initial question was whether the COMPASS decision support system could be implemented 
and used in community settings. The 3,004 completed COMPASS visits provide an 
affirmative response to this question. Further, NAVIGATE participants had on average 
slightly less than twice as many monthly medication management visits (0.554 versus 0.292) 
as Community Care participants and the pattern of more NAVIGATE medication visits was 
present across all trial phases. These findings support the sustained feasibility and 
acceptability of the NAVIGATE treatment model in comparison with usual care. 
NAVIGATE prescribers had the support of a manual, training by the Central Team in 
treatment principles and COMPASS use, the guidance that was built into the COMPASS 
visits and access to monthly teleconferences.
The next key question was whether NAVIGATE recommendations and the COMPASS 
system influenced prescriptions? Regarding antipsychotics, prescriptions for any 
antipsychotic as well as prescriptions conforming to NAVIGATE first-line antipsychotic 
principles were significantly more likely with NAVIGATE compared with Community Care. 
Prescriptions for specific antipsychotics did not differ significantly. At a trend level, 
aripiprazole prescriptions were more likely and haloperidol prescriptions less likely for 
NAVIGATE participants, consistent with NAVIGATE-preferred medication stages. 
Clozapine was required only infrequently with our first-episode population. Rates were 
greater with NAVIGATE than Community Care (4.7% versus 1.8% of months with 
prescription data) but the difference was not significant. Given the NAVIGATE emphasis 
upon low dose strategies, we anticipated that NAVIGATE prescriptions would be for lower 
doses. Instead we found no differences, probably resulting from the finding that the mean 
modal doses for Community Care antipsychotic prescriptions overall were within 
recommended first-episode treatment ranges.
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In a prior analysis of medication prescription at RAISE-ETP entry (29), 39.2% of 
participants were receiving problematic prescriptions. An important question is whether 
rates of problematic medication prescriptions change during extended treatment. Differences 
in data sources available at baseline and longitudinally precluded applying the prior baseline 
criteria to the current longitudinal analyses. Prescriptions that do not conform with 
NAVIGATE first-line principles may be clinically appropriate (e.g. for symptoms that do not 
improve with a first-line medication). Nevertheless, the extent that patients with baseline 
prescriptions not conforming to NAVIGATE first-line principles later receive a first-line 
prescription does provide one metric to evaluate whether prescription patterns improve over 
time. It is encouraging that substantial numbers of Community Care participants receiving 
prescriptions not conforming with NAVIGATE first-line principles eventually received a 
NAVIGATE first-line prescription and that NAVIGATE compared with Community Care 
treatment significantly increased the likelihood of this change.
We earlier reported that NAVIGATE participants had lower depressive symptoms (5). The 
present analysis shows that this was achieved with significantly less likelihood of 
antidepressant prescription. This may reflect the finding that the depressive symptoms of 
patients with first-episode psychosis often remit with antipsychotic treatment alone (21) and 
this information was included in NAVIGATE training. Further, the NAVIGATE psychosocial 
interventions (12) may have contributed to better depression symptom outcomes. A recent 
meta-analysis (30) found small beneficial effects for adjunctive antidepressants for 
depression and negative symptoms with people with schizophrenia. First-episode subgroup 
analyses did not detect effects but the number of first-episode studies included was small. 
Negative symptom outcomes in RAISE-ETP did not differ between conditions despite less 
antidepressant use. Further research is needed to determine 1) whether first-episode 
psychosis specialty care treatment consistently produces better depression outcomes with 
less antidepressant prescription and 2) antidepressant effects (if any) on negative symptoms 
among first-episode patients.
The lower number of side effects among NAVIGATE participants is notable given that 
NAVIGATE participants were more likely to be prescribed antipsychotics and the side 
effects assessed were ones specifically associated with antipsychotic treatment. NAVIGATE 
training emphasized side effect prevention and/or minimization and the COMPASS system 
included structured side effect assessments at each visit and decision support for side effect 
management. These may have contributed to less side effect burden from prevention efforts 
and better detection and treatment of antipsychotic-induced side effects when they occurred. 
The less frequent use of antidepressants at NAVIGATE sites may also have contributed to 
fewer side effects.
Although significant differences between NAVIGATE and Community Care outcomes were 
found for weight gain/BMI, the differences were small in magnitude. Nevertheless, given the 
likely future duration of antipsychotic exposure, such differences are potentially important. 
Given the potential adverse effects of antipsychotics on lipid and glucose metabolism, it is 
reassuring that NAVIGATE treatment enhanced antipsychotic prescription compared with 
Community Care while producing similar laboratory outcomes. Nevertheless, the mean 6.5 
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kg weight gain among NAVIGATE participants shows that additional tools for preventing 
adverse metabolic outcomes are needed.
Medication data from other comparisons of comprehensive first-episode specialty care with 
usual care are limited. Broadly, data from our and other trials (31,32) and from 
demonstration projects (33) suggest that comprehensive care treatment may be associated 
with better medication treatment. Intervention compared with control condition participants 
in the LEO trial were significantly less likely to stop prescribed medication (31) and in the 
OPUS trial more likely at a trend level of significance to be taking an antipsychotic at 1-year 
but not at 2-year follow-up (32).
A limitation of RAISE-ETP medication data is the reliance on patient self-report. Self-report 
was necessary as a source instead of clinic or pharmacy records to permit medication 
tracking for participants who discontinued treatment at their RAISE-ETP site. Patient self-
report may have introduced inaccuracies in the overall data, but should have had limited 
impact on the NAVIGATE versus Community Care comparisons, as participants in both 
conditions should have had equivalent ability to report treatments prescribed. It should be 
noted that our data are for medications prescribed instead of medications taken. The 
Adherence Estimator data documented an advantage with NAVIGATE but not Community 
Care treatment for medication beliefs related to adherence. An important future research 
question is whether these belief changes translate into improved adherence.
In summary, we previously reported differential improvement with the comprehensive 
NAVIGATE treatment model compared to Community Care in quality of life and clinical 
psychopathology outcomes (5). We now add findings of greater frequency of antipsychotic 
prescription, reduced side effect burden, reduced antidepressant prescription, and some 
reduction of the consequences of antipsychotics on medical health. The NAVIGATE model 
of measurement-based care in the context of shared decision making provides a framework 
for incorporating future advances. As knowledge of first-episode medication treatment 
advances, future medication guideline improvements may produce even better outcomes 
than our current efforts.
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Figure 1. 
Least Squares Mean Estimates of Number of Medication Visits by NAVIGATE and 
Community Care Participants
Bars present standard errors
Treatment-by-time interaction, F=3.78, df=23, 9246, p<0.0001; effect of time, F=41.85, 
df=23, 9246, p<0.0001; effect of treatment, F=12.80, df=1, 9246, p=0.0003
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